Subscribe
Chicago, IL—Adding bevacizumab (Avastin) to standard chemotherapy improves overall survival (OS) in women with metastatic or relapsed cervical cancer, representing the first instance in which a targeted therapy has significantly prolonged OS in this patient population.

Data continue to build for the application of immunotherapy for patients with metastatic melanoma. At the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), several sessions were devoted to recent advances in melanoma, focusing on new ways to boost the activity of current therapies, introducing a new class of immunotherapy in development, and a new form of immunotherapy—an oncolytic vaccine.

In a new study published in the Proceeding of the National Academy of Science, scientists have shown that a hormonal pathway different from what was previously thought is driving late-stage prostate cancer tumors.

This new discovery “will change the framework for the way people think about this disease,” said lead investigator Nima Sharifi, MD, a researcher at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center.

A survey-based study from Duke University and Dana-Farber Cancer Institute reveals that insured patients with cancer often face high out-of-pocket (OOP) expenses for their very expensive treatments and prescription drugs. As patients are working less and insurers are shifting more costs to patients, the overall ranks of the underinsured have grown—to 20% in 2007 and likely much more in 2011, said S. Yousuf Zafar, MD, Division of Medical Oncology, Duke University, Durham, NC, during the 2011 annual meeting of the American Society of Clinical Oncology.

Results from the recent National Lung Cancer Screening Trial (NLST) show that screening with low-dose helical computed tomography (CT) can significantly reduce mortality in persons at risk for lung cancer, such as smokers (N Engl J Med. Online, June 29, 2011). Earlier studies have shown that low-dose CT scanning has been able to detect lung cancer earlier than was possible with chest radiography.

Patients with acute myeloid leukemia (AML), the most common form of leukemia, are receiving unnecessarily high doses of chemotherapy, which is above the level needed to generate a dose-response reaction, according to new results reported in June at the 16th Congress of the European Hematology Association.

The US Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee (ODAC) has issued its recommendations to the FDA to withdraw the current indication of bevacizumab (Avastin) in combination with paclitaxel chemotherapy as first-line therapy for previously untreated patients with HER2-negative metastatic breast cancer. Although this is only a recommendation, the agency is known to follow the recommendations by ODAC in most cases. The FDA has not announced when the FDA Commissioner will make the final decision.

Page 2 of 17
Results 11 - 20 of 162
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology